Endpoints Shorts: Dr. Nadia Sethi on Cytokinetics’ Terminated Reldesemtiv Clinical Trial
Please note that the study described in the podcast episode, the COURAGE-ALS Phase 3 Study for reldesemtiv, was terminated on March 31st, 2023 for futility – meaning that an unblinded analysis was conducted on data by an independent committee while the trial was still ongoing, and it was determined that there was no evidence of an effect.
Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute.
In these bite-size podcasts, we’ll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less.
Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI’s Director of Community Outreach and Engagement. Today, Nadia joins us to talk us through Cytokinetics’ phase 3 trial for reldesemtiv.
Please note that the study described in the podcast episode, the COURAGE-ALS Phase 3 Study for reldesemtiv, was terminated on March 31st, 2023 for futility – meaning that an unblinded analysis was conducted on data by an independent committee while the trial was still ongoing, and it was determined that there was no evidence of an effect.
Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute.
In these bite-size podcasts, we’ll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less.
Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI’s Director of Community Outreach and Engagement. Today, Nadia joins us to talk us through Cytokinetics’ phase 3 trial for reldesemtiv.